Resverlogix Corp
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$31.62M
-0.03
19
Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The firm focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The firm's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. The company partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The firm focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The firm's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. The company partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Recently from Cashu
Couldn't load Cashu news
Something went wrong. Try refreshing the page.